Johnson & Johnson (JNJ) Mulls Sale

JNJ may sell its $2.2 billion diagnostics unit for blood and cholesterol tests as the company focuses on genetic screening to complement its drug pipeline.

  • January 24, 2013
  • Manufacturing Group

By Michelle Fay Cortez and Shannon Pettypiece on January 22, 2013 - as originally appeared in Bloomberg Businessweek

Johnson & Johnson (JNJ), the world’s biggest maker of health-care products, may sell its $2.2 billion diagnostics unit for blood and cholesterol tests as the company focuses on genetic screening to complement its drug pipeline.

J&J is reviewing options for the Ortho Clinical Diagnostics division, Chief Executive Officer Alex Gorsky said today at an investor meeting in New York. The unit makes devices for screening blood bank donations and sells more than 120 tests for everything from high cholesterol to fertility hormones.

Read the full story here.

Related